Message from the Director
Stanton L. Gerson, MD
Director, National Center for Regenerative Medicine, CWRU
Director, Case Comprehensive Cancer Center, CWRU
Director, Seidman Cancer Center, UH Cleveland Medical Center
Welcome to the National Center for Regenerative Medicine (NCRM) and thank you for taking time to learn about our most recent accomplishments.
But this report is more than simply a record of our previous year. It is a story of rigorous study and the unselfish willingness of individuals to combine resources for a shared goal. It is the continuation of a much larger story, and one that we have been telling in one format or another for over 30 years:
- The first stem cell transplant in Ohio was performed at University Hospitals Cleveland Medical Center, one of our key affiliates.
- Some of the earliest public patents on stem cells were filed in 1982 by our own Arnold Caplan, PhD. Those patents eventually became a mainstay for the entire industry of cellular therapeutics.
- NCRM itself was initiated in 2003 with support from the State of Ohio, leading to key partnerships with our affiliates and the creation of several private companies.
This year, we have many new and existing projects which we are eager to share. One of those projects is the OH-Alive Innovator Platform working to develop the infrastructure for optimizing new cellular therapies. Another is the recent work involving representatives from three of our major affiliates—Jeffrey Cohen, MD; Hilliard Lazarus, MD; and Arnold Caplan, PhD—who pooled their considerable knowledge to drive a new idea in the study and application of mesenchymal stem cells in Multiple Sclerosis. We are especially excited about our current work in Induced Pluripotent Stem (iPS) cells, cancer stem cells, and stem cell gene therapy. These could identify the next generation of treatments emerging from our scientific discoveries.
If there is one key aspect that we would like you to take from our story, it is the understanding that the NCRM is founded on a bedrock of collaboration and commitment. We are highly appreciative that our prominence in the field comes from the unique confluence of these partnerships, and we are so grateful for the opportunity to continue them far into the future of modern cell-based therapies.
Stan L. Gerson, MD